IMDX Submits GraftAssureDx for FDA Review, Reports Q4 2025 Results
Event summary
- IMDX submitted GraftAssureDx for FDA review on March 25, 2026, marking the first kitted dd-cfDNA assay submission.
- The company reported Q4 2025 revenue of $1.1 million, with full-year revenue at $4.1 million.
- IMDX completed a $26 million financing in February 2026 to support expansion into heart transplantation.
- The company expects U.K. CE marking via self-certification in Q2 2026.
- IMDX engaged with 37 U.S. transplant centers and 11 internationally for GraftAssureDx.
The big picture
IMDX's submission of GraftAssureDx for FDA review represents a critical milestone in the transplant diagnostics market, which is shifting towards decentralized, in-house testing. The company's strategic focus on expanding into heart transplantation and securing regulatory approvals positions it to capture a significant share of the $2 billion addressable market for transplant rejection testing. The recent financing and favorable head-to-head data further strengthen IMDX's competitive stance as it transitions from product development to commercialization.
What we're watching
- Regulatory Timelines
- Whether IMDX can secure FDA authorization within the 150-day review period, given the potential for reviewer questions.
- Market Adoption
- The pace at which transplant centers adopt GraftAssureDx post-FDA approval, particularly given the growing interest from 37 U.S. centers.
- Competitive Positioning
- How IMDX's head-to-head data against competitors will influence clinician confidence and market share.
Related topics